Oropharyngeal cancer is cancer that forms in the middle part of the throat, just behind the mouth. This region, called the oropharynx, includes the base of the tongue, the tonsils, the soft palate, and the walls of the throat. Between 60% and 70% of oropharyngeal cancers in the United States are caused by human papillomavirus (HPV), which has fundamentally changed how this cancer is understood, staged, and treated.
Where the Oropharynx Is
The oropharynx sits between the back of your mouth and the upper part of your throat. Its boundaries run from the soft palate on top down to a fold near the base of the tongue. The structures packed into this small space include the soft palate, the tonsils on either side, the back third of the tongue (called the base of tongue), and bands of lymphoid tissue along the throat walls. Most oropharyngeal cancers start in the tonsils or at the base of the tongue.
HPV and Other Causes
HPV infection, specifically HPV type 16, is the dominant driver of oropharyngeal cancer in the U.S. The virus can persist in throat tissue for years or even decades before triggering cancerous changes. HPV-related oropharyngeal cancer is far more common in men than women, and incidence is highest in men aged 45 and older.
Tobacco and alcohol use remain significant risk factors, particularly for HPV-negative oropharyngeal cancers. These cases tend to occur in older adults with long histories of smoking and heavy drinking. The two habits together amplify risk beyond what either would cause alone.
A notable trend has emerged in recent years. Among adults under 45, oropharyngeal cancer rates have actually declined, with a significant turning point around 2008 in young men, coinciding with the early years of widespread HPV vaccination. Meanwhile, rates continue to rise in men and women aged 45 and older, reflecting HPV infections acquired long before the vaccine became available.
Symptoms to Recognize
Oropharyngeal cancer sometimes causes no symptoms in its early stages. When signs do appear, they can include:
- A sore throat that doesn’t resolve over several weeks
- A lump in the neck, often painless, caused by cancer spreading to lymph nodes
- Difficulty swallowing or a feeling that something is stuck in the throat
- Ear pain on one side, which occurs because the throat and ear share nerve pathways
- Trouble opening the mouth fully or moving the tongue
- A white or red patch on the tongue or inner lining of the mouth that persists
- Coughing up blood
- Unexplained weight loss
A painless neck lump is one of the most common first signs, especially in HPV-positive cases. Many people initially assume it’s a swollen lymph node from an infection, which can delay diagnosis.
How It’s Diagnosed
Diagnosis begins with a physical exam of the mouth and throat, often followed by endoscopy, where a thin flexible camera is passed through the nose to get a close look at the oropharynx. If anything suspicious is found, a biopsy confirms whether cancer is present. For tumors at the base of the tongue, deep endoscopic biopsies are sometimes the only way to distinguish cancer from normal lymphoid tissue, which is naturally lumpy in that area.
Once cancer is confirmed, the tumor is tested for HPV status using a protein marker called p16. This single test result shapes nearly every decision that follows, from how the cancer is staged to what treatment looks like and what outcomes to expect.
Why HPV Status Changes the Staging
The cancer staging system was overhauled in 2018 specifically because HPV-positive and HPV-negative oropharyngeal cancers behave so differently. Under the current system, HPV-positive tumors get their own, separate staging criteria. The practical effect is that an HPV-positive cancer that has spread to several lymph nodes on one side of the neck may still be classified as Stage I, whereas the same spread in an HPV-negative cancer would be staged much higher.
This isn’t arbitrary. HPV-positive oropharyngeal cancer responds dramatically better to treatment. Under the old system, many HPV-positive patients were being staged as advanced cancer and potentially overtreated for a disease that had an excellent prognosis.
Survival Rates by HPV Status
The gap in outcomes between HPV-positive and HPV-negative oropharyngeal cancer is one of the starkest in all of oncology. One study tracking patients for five years after treatment with radiation and chemotherapy found that the disease-specific survival rate was 85.7% for HPV-positive patients compared to 11.1% for HPV-negative patients. While results vary across studies, the overall pattern holds: HPV-positive oropharyngeal cancer has a significantly better prognosis, with five-year survival rates generally ranging from 75% to 90% depending on the stage.
HPV-negative oropharyngeal cancer, typically associated with long-term tobacco and alcohol use, tends to respond less well to treatment and carries a much higher risk of recurrence.
Treatment Options
For early-stage oropharyngeal cancer, the two primary approaches are radiation therapy and surgery, sometimes combined with chemotherapy.
Radiation therapy, delivered using a highly targeted technique called intensity-modulated radiation therapy (IMRT), is the conventional first-line treatment. IMRT shapes the radiation beam to focus on the tumor while sparing surrounding structures like the salivary glands and swallowing muscles, which reduces side effects like chronic dry mouth and difficulty eating.
Surgery has evolved considerably with robotic technology. Transoral robotic surgery (TORS) allows surgeons to remove tumors through the mouth without external incisions, reaching deep structures at the base of the tongue and tonsils with precision. Rates of feeding tube dependence after TORS are low, ranging from 0% to 7%, comparable to the roughly 4% rate after IMRT alone. One practical advantage of surgery first is that it can reduce the dose of radiation needed afterward, which translates to fewer long-term side effects from treatment.
For more advanced cases, treatment typically involves radiation combined with chemotherapy. The chemotherapy drug most commonly paired with radiation is a platinum-based agent that makes cancer cells more sensitive to the radiation. In some cases, chemotherapy is given before surgery or radiation to shrink the tumor first.
What Recovery Looks Like
Regardless of the approach, treatment for oropharyngeal cancer affects basic daily functions: swallowing, speaking, and taste. During radiation, most people experience a progressively sore throat, difficulty eating, changes in taste, and fatigue. These effects peak toward the end of treatment and gradually improve over weeks to months afterward. Some degree of dry mouth can persist long term, though IMRT has significantly reduced this compared to older radiation techniques.
After TORS, recovery from the surgery itself is typically faster than with traditional open surgery, though swallowing rehabilitation is still an important part of the process. Many patients work with a speech and swallowing therapist during and after treatment.
HPV Vaccination and Prevention
The FDA has approved the HPV vaccine for individuals aged 9 through 45 for the prevention of HPV-related cancers, including oropharyngeal cancer. This approval was based on the established effectiveness of the vaccine against HPV infections at other body sites, combined with epidemiologic evidence that preventing persistent oral HPV infection is reasonably likely to prevent throat cancer down the line. A confirmatory study is currently underway.
Population-level data already suggests a real-world effect. The decline in oropharyngeal cancer rates among adults under 45 in the U.S. aligns with the rollout of HPV vaccination programs, particularly among young men, where a clear inflection point in incidence appeared around 2008. For HPV-negative disease, avoiding tobacco and limiting alcohol remain the most effective preventive measures.